IL105883A - Tissue plasminogen activator glycosylation variants, glycosylated at any one of positions 103 to 105 and devoid of glycosylation at position 117, with improved therapeutic properties, method of preparing and compositions comprising them - Google Patents

Tissue plasminogen activator glycosylation variants, glycosylated at any one of positions 103 to 105 and devoid of glycosylation at position 117, with improved therapeutic properties, method of preparing and compositions comprising them

Info

Publication number
IL105883A
IL105883A IL10588393A IL10588393A IL105883A IL 105883 A IL105883 A IL 105883A IL 10588393 A IL10588393 A IL 10588393A IL 10588393 A IL10588393 A IL 10588393A IL 105883 A IL105883 A IL 105883A
Authority
IL
Israel
Prior art keywords
glycosylation
glycosylated
devoid
positions
plasminogen activator
Prior art date
Application number
IL10588393A
Other languages
English (en)
Other versions
IL105883A0 (en
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL105883A0 publication Critical patent/IL105883A0/xx
Publication of IL105883A publication Critical patent/IL105883A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL10588393A 1992-06-03 1993-06-02 Tissue plasminogen activator glycosylation variants, glycosylated at any one of positions 103 to 105 and devoid of glycosylation at position 117, with improved therapeutic properties, method of preparing and compositions comprising them IL105883A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89421392A 1992-06-03 1992-06-03

Publications (2)

Publication Number Publication Date
IL105883A0 IL105883A0 (en) 1993-10-20
IL105883A true IL105883A (en) 2003-04-10

Family

ID=25402765

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10588393A IL105883A (en) 1992-06-03 1993-06-02 Tissue plasminogen activator glycosylation variants, glycosylated at any one of positions 103 to 105 and devoid of glycosylation at position 117, with improved therapeutic properties, method of preparing and compositions comprising them

Country Status (20)

Country Link
US (1) US5612029A (et)
EP (2) EP0643772B1 (et)
JP (1) JP3559559B2 (et)
AT (2) ATE246000T1 (et)
AU (1) AU664469B2 (et)
CA (1) CA2129660C (et)
DE (3) DE69333127T2 (et)
DK (2) DK0643772T3 (et)
EE (1) EE03128B1 (et)
ES (2) ES2203668T3 (et)
FI (1) FI117940B (et)
GE (1) GEP20012448B (et)
GR (1) GR3024806T3 (et)
HK (2) HK1000449A1 (et)
IL (1) IL105883A (et)
LU (1) LU90800I2 (et)
NL (1) NL300050I2 (et)
NZ (1) NZ253556A (et)
PT (1) PT786257E (et)
WO (1) WO1993024635A1 (et)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013385A2 (en) * 1993-11-12 1995-05-18 Gilead Sciences Thrombin mutants
US7060484B1 (en) 1993-11-12 2006-06-13 Gilead Sciences, Inc. Polypeptides and coagulation therapy
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5510330A (en) † 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
DE4423574A1 (de) * 1994-07-05 1996-01-11 Boehringer Mannheim Gmbh Nicht-glykosylierte Plasminogenaktivator-Derivate und ihre Verwendung bei erhöhtem Blutungsrisiko
US5945432A (en) * 1995-12-22 1999-08-31 The University Of Vermont And State Agricultural College Thrombolytic agents and thienopyridine derivatives in acute stroke
AU2660397A (en) * 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US6083715A (en) * 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
AU1208599A (en) * 1997-10-31 1999-05-24 Eli Lilly And Company Glycosylated obesity protein analogs
US6242473B1 (en) 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
AU781023B2 (en) 1999-11-04 2005-04-28 Genentech Inc. Reversed-phase HPLC assay for plasminogen activators
US20030036181A1 (en) * 2000-06-30 2003-02-20 Okkels Jens Sigurd Peptide extended glycosylated polypeptides
NZ532074A (en) * 2001-11-06 2006-02-24 Maxim Pharm Inc Compositions for the treatment of infectious diseases
CA2467645C (en) * 2001-11-26 2017-01-17 Genentech, Inc. Composition for removing fibrin-bound blood clots from a catheter
US7084118B2 (en) * 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
US20060105387A1 (en) * 2002-08-30 2006-05-18 Prior Christopher P Transferrin fusion proteins libraries
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
WO2006023530A2 (en) * 2004-08-16 2006-03-02 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
RU2007147921A (ru) * 2005-06-02 2009-07-20 Эйвестаджен Лимитед,In (In) Оптимизированный способ получения рекомбинантной формы тканевого активатора плазминогена
WO2007030652A2 (en) * 2005-09-08 2007-03-15 University Of Virginia Patent Foundation Methods and compositions for growing adipose stem cells
WO2007120818A2 (en) * 2006-04-12 2007-10-25 Massachusetts Institute Of Technology Compositions and methods for inhibiting adhesions
WO2007120847A2 (en) * 2006-04-14 2007-10-25 Massachusetts Institute Of Technology Identifying and modulating molecular pathways that mediate nervous system plasticity
SG10201804944XA (en) 2006-08-29 2018-07-30 Genentech Inc Use of tenecteplase for treating acute ischemic stroke
JP2010505849A (ja) * 2006-10-06 2010-02-25 ユニバーシティ オブ バージニア パテント ファウンデーション 糖尿病性創傷治癒に有用な方法および組成物
JP5871449B2 (ja) 2006-11-07 2016-03-01 ジェネンテック， インコーポレイテッド 組織プラスミノゲン活性化因子バリアントの使用
KR100834561B1 (ko) 2006-12-08 2008-06-02 가톨릭대학교 산학협력단 크링글 도메인 1 및 2로 이루어진 비-글리코실화 재조합단백질, 그 제조 방법 및 이를 포함하는 조성물
EP2289541A1 (en) 2009-08-31 2011-03-02 PAION Deutschland GmbH Treatment of neurological or neurodegenerative disorders
EP2289542A1 (en) 2009-08-31 2011-03-02 PAION Deutschland GmbH Treatment of neurological or neurodegenerative disorders
US20130122076A1 (en) * 2011-11-11 2013-05-16 Mathew Gelfand Transdermal Patch Having Ultrasound Transducer for Administering Thrombolytic Reagents to Patients Having a Protein Misfolding Disease
EP2869834B1 (en) * 2012-07-05 2019-12-11 Hadasit Medical Research Services & Development Limited Plasminogen activator mutants as anti-fibrinolytic agents
WO2014089327A1 (en) 2012-12-05 2014-06-12 National Jewish Health Treatment for airway cast obstruction
CN103159860B (zh) * 2013-04-07 2014-09-24 旭华（上海）生物研发中心有限公司 重组组织型纤溶酶原激活剂及其制备方法与用途
US10220008B2 (en) 2013-08-14 2019-03-05 Stc.Unm Treatment and prevention of stroke and other neurological disorders
WO2016073514A2 (en) * 2014-11-03 2016-05-12 Thrombolytic Science, Llc Methods and compositions for safe and effective thrombolysis
SG11201906530TA (en) 2017-02-03 2019-08-27 Acticor Biotech Inhibition of platelet aggregation using anti-human gpvi antibodies
JP2020520386A (ja) 2017-05-16 2020-07-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 急性虚血性脳卒中の処置のための方法及び医薬組成物
WO2018232305A1 (en) 2017-06-16 2018-12-20 Thrombolytic Science, Llc Methods and compositions for thrombolysis
WO2019238933A1 (en) 2018-06-15 2019-12-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pi3kc2b inhibitors for the preservation of vascular endothelial cell barrier integrity
WO2021148439A1 (en) 2020-01-21 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stimulating cerebrovascular function
US20240207190A1 (en) 2020-06-09 2024-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Fucoidan-functionalized polysaccharide particles with t-pa for targeted thrombolytic therapy
WO2023156683A1 (en) 2022-02-21 2023-08-24 Acticor Biotech Treatment of cardiovascular diseases using anti-human gpvi antibodies

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NL8003402A (nl) 1980-06-11 1982-01-04 Leuven Res & Dev Vzw Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking.
IL68561A (en) 1982-05-05 1991-01-31 Genentech Inc Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
WO1984001960A1 (en) * 1982-11-11 1984-05-24 Beecham Group Plc Pharmaceutically active compounds
EP0112122B1 (en) * 1982-12-14 1991-08-28 South African Inventions Development Corporation Plasminogen activator
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4658830A (en) * 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
US4753879A (en) * 1984-08-27 1988-06-28 Biogen N.V. Modified tissue plasminogen activators
NO175158C (no) * 1984-10-01 1994-09-07 Genzyme Corp Fremstilling av human livmorsvevplasminogenaktivator med rekombinant-DNA
DE3537176C2 (de) * 1984-10-18 1994-06-09 Zymogenetics Inc Gewebeplasminogenaktivator und Verfahren zu seiner Herstellung
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
EP0201153A3 (en) * 1985-02-09 1987-10-07 Beecham Group Plc Modified enzyme and process for its preparation
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
NZ215660A (en) * 1985-04-04 1990-03-27 Beecham Group Plc Tissue plasminogen activator modified in the growth factor domain
IL78571A (en) * 1985-04-22 1991-06-30 Genentech Inc Human tissue plasminogen activator mutants resistant to enzymatic cleavage resulting in two-chain form
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
NL8601354A (nl) * 1985-05-28 1986-12-16 Wellcome Found Nieuwe samenstelling.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
US4960702A (en) * 1985-09-06 1990-10-02 Codon Methods for recovery of tissue plasminogen activator
DE3687255T2 (de) * 1985-09-10 1993-05-06 Eisai Co Ltd Einen gewebe-plasminogen-aktivator enthaltende zusammensetzung.
GB8528321D0 (en) * 1985-11-18 1985-12-24 Ciba Geigy Ag Modified fibrinolytic agents
DE3687651T2 (de) * 1985-12-20 1993-06-24 Upjohn Co Analoge des gewebespezifischen plasminogenaktivators.
AU605124B2 (en) 1985-12-23 1991-01-10 Behringwerke Aktiengesellschaft Novel peptide plasminogen activators
DK43387A (da) * 1986-01-29 1987-07-30 Beecham Group Plc Fibrinolytisk enzym
WO1987004722A1 (en) * 1986-01-31 1987-08-13 Genetics Institute, Inc. Novel thrombolytic proteins
IE81073B1 (en) 1986-03-18 2000-01-12 Genentech Inc Modified human tissue-type plasminogen activator and its preparation
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
PT84587B (pt) 1986-04-02 1989-11-30 Beecham Group Plc Processo para preparacao de uma enzima fibrinolitica
PT84588B (en) 1986-04-02 1989-05-09 Beecham Group Plc Process for preparing a fibrinolytic enzyme
PT84589B (en) * 1986-04-02 1989-05-09 Beecham Group Plc Process for preparing a fibrinolytic enzyme
DE3643158A1 (de) * 1986-04-21 1987-11-19 Boehringer Mannheim Gmbh Gewebs-plasminogen-aktivator(tpa) - derivat und seine herstellung
JPH0761266B2 (ja) * 1986-07-03 1995-07-05 株式会社ミドリ十字 変異ヒトプロウロキナ−ゼ
DK345087A (da) * 1986-07-11 1988-01-12 Novo Industri As Modificeret vaevsplasminogenaktivator
GB8619098D0 (en) * 1986-08-05 1986-09-17 Wellcome Found Combination
EP0266032A1 (en) * 1986-08-29 1988-05-04 Beecham Group Plc Modified fibrinolytic enzyme
WO1988005081A2 (en) * 1986-12-30 1988-07-14 Cetus Corporation Novel plasminogen activator
GB8705377D0 (en) * 1987-03-07 1987-04-08 Beecham Group Plc Compounds
DK275788A (da) * 1987-05-22 1989-02-03 Zymogenetics Inc Fibrinolytiske proteiner
DK302388A (da) * 1987-06-04 1989-02-03 Zymogenetics Inc T-pa analoger med dodificeret vaekstfaktordomaene
ES2058180T3 (es) * 1987-06-04 1994-11-01 Zymogenetics Inc T-pa mutante con reemplazo de kringle.
SE8702562L (sv) * 1987-06-18 1988-12-19 Kabigen Ab Nya fibrinolytiska enzymer
HUT51901A (en) * 1987-06-22 1990-06-28 Genetics Inst Process for production of new trombolitic ensimes
WO1989000197A1 (en) * 1987-06-30 1989-01-12 Genentech, Inc. Improved processes for the treatment of vascular disease
US4935237A (en) 1988-03-21 1990-06-19 Genentech, Inc. Processes for the preparation of t-PA mutants
JPH03500002A (ja) * 1987-07-06 1991-01-10 ジェネティックス・インスチチュート・インコーポレーテッド 新規な血栓崩壊蛋白
AU1893988A (en) * 1987-07-13 1989-01-19 Collaborative Research Inc. Nonglycosylated plasminogen activator and method of preparation
DK468388A (da) 1987-08-21 1989-02-22 Wellcome Found Kompleks af polyethylenglycol og vaevplasminogen-aktivator, fremgangsmaade til dets fremstilling og farmaceutiske kompositioner indeholdende komplekset
IL88247A0 (en) 1987-11-06 1989-06-30 Genentech Inc Novel human tissue-type plasminogen activator variant
US5225540A (en) 1988-04-26 1993-07-06 Du Pont Merck Pharmaceutical Company Monoclonal antibodies to tissue plasminogen activator (t-pa) which prolong its functional half-life
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
IL90146A (en) 1988-05-20 1994-10-07 Genentech Inc Glycosylation derivatives of tissue plasminogen activator
US5342616A (en) * 1988-06-20 1994-08-30 The Wellcome Foundation Limited Method of administering tissue plasminogen activator
GB8815135D0 (en) 1988-06-24 1988-08-03 British Bio Technology Proteins & nucleic acids
DK395288D0 (da) * 1988-07-15 1988-07-15 Novo Industri As Proteiner
US5258180A (en) * 1988-09-02 1993-11-02 Genetech, Inc. Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5108901A (en) * 1988-09-02 1992-04-28 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
ES2185529T3 (es) * 1989-03-06 2003-05-01 Univ Texas T-pa resistente a la serpina; mutante; genes.
US5304482A (en) * 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
ATE144281T1 (de) 1989-04-28 1996-11-15 Rhein Biotech Proz & Prod Gmbh Hefezellen der gattung-schwanniomyces
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5087572A (en) 1989-12-01 1992-02-11 Genentech, Inc. Dna encoding human plasminogen modified at the cleavage site
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
US5366730A (en) * 1989-12-20 1994-11-22 Boehringer Mannheim Gmbh Stabilized compositions having human tissue type plasminogen activator enzymatic activity
WO1992002612A2 (en) 1990-07-31 1992-02-20 Genentech, Inc. Tissue plasminogen activator variants with decreased clearance
US5246850A (en) * 1990-07-31 1993-09-21 Genentech, Inc. DNA molecules encoding human tissue plasminogen activator variants with decreased clearance, vectors, and host cells
US5242688A (en) * 1990-12-24 1993-09-07 Eli Lilly And Company Method of treating thromboembolic disorders by administration of diglycosylated t-pa variants

Also Published As

Publication number Publication date
FI117940B (fi) 2007-04-30
NL300050I2 (nl) 2001-11-01
GEP20012448B (en) 2001-05-25
EP0643772A1 (en) 1995-03-22
US5612029A (en) 1997-03-18
FI943632A (fi) 1994-10-04
JPH07507448A (ja) 1995-08-24
DE10199044I2 (de) 2006-02-09
NL300050I1 (nl) 2001-10-01
DE69312493D1 (de) 1997-09-04
DE10199044I1 (de) 2002-02-21
ATE246000T1 (de) 2003-08-15
CA2129660A1 (en) 1993-12-09
FI943632A0 (fi) 1994-08-04
DE69333127D1 (de) 2003-09-04
WO1993024635A1 (en) 1993-12-09
DK0643772T3 (da) 1998-02-02
EP0643772B1 (en) 1997-07-23
AU4397393A (en) 1993-12-30
DE69312493T2 (de) 1998-01-15
HK1001190A1 (en) 1998-05-29
AU664469B2 (en) 1995-11-16
HK1000449A1 (en) 2004-03-05
CA2129660C (en) 2005-06-28
EE03128B1 (et) 1998-10-15
ATE155816T1 (de) 1997-08-15
DE69333127T2 (de) 2004-05-06
ES2107041T3 (es) 1997-11-16
DK0786257T3 (da) 2003-10-06
NZ253556A (en) 1995-11-27
ES2203668T3 (es) 2004-04-16
PT786257E (pt) 2003-12-31
JP3559559B2 (ja) 2004-09-02
LU90800I2 (fr) 2001-10-08
GR3024806T3 (en) 1998-01-30
EP0786257A1 (en) 1997-07-30
EP0786257B1 (en) 2003-07-30
IL105883A0 (en) 1993-10-20

Similar Documents

Publication Publication Date Title
IL105883A (en) Tissue plasminogen activator glycosylation variants, glycosylated at any one of positions 103 to 105 and devoid of glycosylation at position 117, with improved therapeutic properties, method of preparing and compositions comprising them
IL80659A0 (en) Modified tissue plasminogen activators,their preparation and pharmaceutical compositions containing them
BE2013C033I2 (et)
IL89500A0 (en) Human tissue plasminogen activator variants and processes
GR3019328T3 (en) Vampire bat salivary Plasminogen activator vPA-alpha 1
HU912739D0 (en) Stabilization of glycozylized tissue plasminogene activator (t-pa)
DE59005128D1 (de) t-PA pro STABILISIERUNG.
AU7696087A (en) Recombinant human tissue plasminogen activator composition
IE871856L (en) "modified tissue plasminogen activator"

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired